Anthracycline-containing regimens for treatment of follicular lymphoma in adults

Keyphrases

• Follicular Lymphoma 100%
• Anthracyclines 100%
• Confidence Interval 36%
• Risk Ratio 26%
• Disease Control 21%
• Overall Survival 21%
• Hazard Ratio 15%
• Chemotherapy 10%
• Randomized Controlled Trial 10%
• Remission 10%
• Cardiotoxicity 10%
• Chemotherapeutic Regimens 10%
• Progression-free Survival 10%
• Risk Response 10%
• Adult Patients 5%
• Patient Management 5%
• MEDLINE 5%
• Meta-analysis 5%
• Complete Response 5%
• Rate of Increase 5%
• Search Methods 5%
• Risk Reduction 5%
• Cochrane Library 5%
• Selection Criteria 5%
• Extracted Data 5%
• Unblinding 5%
• Conference Proceedings 5%
• Stem Cell Transplantation 5%
• Fixed Effects Model 5%
• Serious Infection 5%
• Chemotherapy Regimen 5%
• Control Arm 5%
• Lymphoma Patients 5%
• Hazard Risk 5%
• Peer-reviewed Journals 5%
• Control Hazard 5%
• Cochrane Central Register of Controlled Trials 5%
• Trial Data 5%
• Rituximab 5%
• Review Authors 5%
• Issue 3 5%
• Small Databases 5%
• Naïve Patients 5%
• Outcome Definition 5%
• Radiotherapy Alone 5%
• Cytopenia 5%
• Therapy-naïve 5%
• Health Sciences Libraries 5%

Nursing and Health Professions

• Follicular Lymphoma 100%
• Anthracycline 100%
• Confidence Interval 36%
• Disease Control 21%
• Overall Survival 21%
• Hazard Ratio 15%
• Immunotherapy 10%
• Remission 10%
• Cochrane Library 10%
• Progression Free Survival 10%
• Cardiotoxicity 10%
• Chemotherapy 10%
• Infection 5%
• Meta Analysis 5%
• Side Effect 5%
• Rituximab 5%
• Stem Cell Therapy 5%
• Cytopenia 5%
• Radiotherapy 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Follicular Lymphoma 100%
• Anthracycline 100%
• Overall Survival 21%
• Diseases 21%
• Chemotherapy 15%
• Randomized Controlled Trial 10%
• Remission 10%
• Immunotherapy 10%
• Cardiotoxicity 10%
• Progression Free Survival 10%
• Side Effect 5%
• Infection 5%
• Rituximab 5%
• Cytopenia 5%